The Blanket Regulatory Asymmetry Between Transgenic and Gene-Edited Crops Is Not Scientifically Proportionate to Risk

In September 2021, Japanese consumers purchased the world's first commercially available gene-edited food: the Sicilian Rouge High GABA tomato, engineered by Sanatech Seed using CRISPR-Cas9 to accumulate four to five times the normal concentration of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain. No safety evaluation was required. The Japanese government had decided, in 2019, that organisms carrying site-directed nuclease (SDN-1) modifications—small, targeted deletions or substitutions with no foreign DNA in the final product—fell outside the scope of living modified organism regulations. A notification to the Ministry of Health, Labour and Welfare was sufficient. Had Sanatech instead inserted a single transgene encoding the same biosynthetic enzyme from another plant species, the identical tomato would have faced years of confined field trials, compositional analyses, allergenicity testing, and environmental risk assessment before reaching a single consumer.

This article argues that the blanket regulatory distinction between transgenic and gene-edited crops, as currently codified across most jurisdictions, is not proportionate to the actual differences in risk between the two categories. To be clear: some regulatory differentiation has scientific grounding. The presence or absence of foreign DNA, the detectability of the modification, and the degree of ecological novelty introduced by a given edit are legitimate variables that should inform oversight. What lacks justification is the binary architecture that most regulatory systems impose—treating all gene-edited organisms either as full GMOs or as entirely unregulated, depending on the jurisdiction, rather than calibrating scrutiny to the biological properties of the specific organism. That architecture is largely the fossilized residue of regulations built in the 1980s around recombinant DNA as a process trigger. Four decades of plant genomics have exposed its inadequacy. Replacing it with a risk-proportionate, product-based framework is not a concession to industry. It is a prerequisite for evidence-based governance of agricultural innovation.

The Molecular Distinction That Isn't

The regulatory divide between transgenic and gene-edited crops rests on a simple premise: that introducing foreign DNA differs categorically from modifying endogenous sequences. Regulators in the European Union operationalized this through a process-based framework triggered not by the properties of the resulting organism but by the technique used to produce it. The EU's Directive 2001/18/EC, governing the deliberate release of genetically modified organisms (GMOs), was drafted when recombinant DNA was the only method capable of producing heritable changes unachievable through conventional breeding. The directive exempted organisms produced by mutagenesis—random chemical or radiation-induced mutations—on the assumption these techniques had a long safety record.

The problem is direct. CRISPR-Cas9 and related site-directed nucleases produce molecular outcomes indistinguishable from those generated by the exempted mutagenesis techniques. They do so with far greater precision. A single-nucleotide deletion induced by CRISPR in the coding sequence of a wheat grain hardness gene is, at the DNA level, identical to one arising spontaneously or through ethyl methanesulfonate (EMS) mutagenesis. A 2021 study in Horticulture Research using whole-genome sequencing of CRISPR-edited grapevines identified only a single off-target insertion-deletion across the entire genome, even after prolonged Cas9 expression. By contrast, chemical mutagenesis routinely introduces mutation densities ranging from one single-nucleotide polymorphism per 50 base pairs to one per 2,500 kilobases. This burden dwarfs the off-target load of CRISPR-Cas systems by orders of magnitude.

This is not peripheral. It strikes at the core logic of the regulatory framework. If the exemption for conventional mutagenesis rests on decades of use, then a technique producing fewer unintended genomic alterations than conventional mutagenesis cannot rationally face more stringent oversight. For the most common category of gene edits, the regulatory asymmetry does not track with molecular risk. It tracks with the historical accident of which techniques existed when regulations were written.

Not All Gene Editing Is Equivalent: The SDN Tier Distinction

A critical nuance that blanket regulatory frameworks routinely obscure: gene editing is not a single technique producing a single type of outcome. The scientific literature distinguishes three categories of site-directed nuclease (SDN) modifications, and they carry meaningfully different risk profiles.

SDN-1 edits, by far the most common application in crop improvement, produce plants that are transgene-free and whose modifications cannot be distinguished from spontaneous mutations or conventional mutagenesis by any analytical method. SDN-2 edits are similarly contained within the species' existing allelic diversity. SDN-3 edits, by contrast, can introduce foreign genetic material at a predetermined genomic location—functionally a more precise form of transgenesis. The risk profile of an SDN-3 insertion of a bacterial insecticidal protein gene is categorically different from the risk profile of an SDN-1 knockout of an endogenous susceptibility gene.

This distinction matters because regulatory systems that treat "gene editing" as a monolithic category—whether to exempt it entirely or to subject it wholesale to GMO oversight—fail on their own terms. Health Canada's 2023 scientific opinion concluded that gene editing does not inherently create new classes of food-safety hazards compared with other breeding methods; hazard arises from the trait, not the technique. An SDN-1 edit that knocks out a single endogenous gene does not warrant the same regulatory apparatus as an SDN-3 insertion of a synthetic gene cassette from a distant taxon. A system that treats them identically—whether with maximal scrutiny or minimal oversight—is not calibrated to risk.

A Global Patchwork Built on Politics, Not Evidence

Divergence across national regulatory systems confirms the transgenic/gene-edited distinction is political rather than scientific. Consider the three largest economies governing crop biotechnology.

In the United States, the Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) finalized the SECURE rule in 2020, shifting regulatory oversight from the presence of plant-pest DNA to the mechanism of action of the modified trait. Under SECURE, gene-edited plants producing traits achievable through conventional breeding were exempt from regulation entirely. This was a partial shift toward product-based assessment. In December 2024, the U.S. District Court for the Northern District of California vacated the SECURE rule, finding that APHIS had inadequately addressed its statutory obligations regarding noxious weeds. The United States reverted to its pre-2020 regulatory framework, one designed around a process trigger that has no bearing on the actual risk profile of a gene-edited crop.

In the European Union, the Court of Justice ruled in July 2018 (Case C-528/16) that organisms produced by directed mutagenesis techniques, including CRISPR-Cas9, constitute GMOs within the meaning of Directive 2001/18/EC and are therefore subject to its full regulatory requirements. The Court acknowledged the mutagenesis exemption was intended only for techniques with a "long safety record." By definition, no recently developed technique can satisfy that criterion, regardless of demonstrated precision. The ruling was internally consistent as legal interpretation. As science, it was indefensible: it classified a single-nucleotide deletion achieved by CRISPR as a GMO while exempting plants carrying thousands of random mutations induced by gamma irradiation, simply because the latter technique predated the directive.

The European Commission recognized this absurdity. In July 2023, it tabled a proposal for a regulation on plants produced by new genomic techniques (NGTs), establishing two categories. Category 1 (NGT-1) plants—those carrying modifications that "could occur naturally or by conventional breeding"—would be exempt from GMO risk assessment and labeling. Category 2 (NGT-2) plants, carrying changes unachievable by conventional means, would remain under the full GMO framework. The Council and Parliament reached a provisional agreement on this framework in December 2025, with the regulation expected to take effect in 2028. This is progress, but the two-year implementation delay means European researchers will operate under a scientifically incoherent regime for a full decade after the 2018 Court ruling.

Argentina established the first national regulatory framework specifically addressing new breeding techniques and has treated gene-edited crops without transgenic insertions as non-GMO since 2015. Japan followed in 2019. As of early 2025, 24 countries have enacted legislation permitting genome-edited plants, with another 37 actively developing regulatory frameworks, according to a comprehensive survey published in npj Science of Plants. The trajectory is clear. The pace, however, is dictated by political negotiation, not by any unresolved scientific question about comparative risk.

The Detection Problem Exposes the Logical Failure

Process-based regulation depends on an unstated assumption: that the process can be detected in the product. For transgenic crops, this holds. The presence of a transgene—a bacterial phosphinothricin acetyltransferase gene conferring herbicide tolerance, for instance—can be identified by polymerase chain reaction (PCR). The foreign sequence is a molecular signature of the process.

For SDN-1 gene edits, this assumption collapses entirely. A single-nucleotide deletion in an endogenous gene is analytically indistinguishable from a spontaneous mutation. No laboratory method can determine whether a given point mutation arose from CRISPR-Cas9, from EMS treatment, or from background replication error. A 2025 review in Frontiers in Bioengineering and Biotechnology identifies this analytical indistinguishability as a fundamental barrier to enforcement of process-based regulations for gene-edited crops.

The enforcement implications are not trivial. The EU's 2018 ruling, strictly applied, means a CRISPR-edited wheat variety carrying a single-nucleotide change in a starch biosynthesis gene would require full GMO authorization, traceability documentation, and labeling. The same mutation arising spontaneously in a farmer's field would be unregulated. The two plants are molecularly identical. There is no possible method to tell them apart. A regulatory framework whose compliance cannot be verified by any existing technology is not precautionary. It is performative.

This detectability gap also creates asymmetric trade barriers. An Argentine soybean variety carrying an SDN-1 edit, legally unregulated in Buenos Aires, becomes an unauthorized GMO upon entering a European port. This occurs despite the impossibility of detecting the edit in a grain shipment. The regulatory asymmetry does not protect European consumers from quantifiable risk. It imposes a compliance burden that is technically unenforceable and scientifically unjustified, while disadvantaging trading partners who adopted evidence-based frameworks.

Where Regulatory Differentiation Has Scientific Grounding

Intellectual honesty requires acknowledging what the blanket-asymmetry critique sometimes elides: there are legitimate scientific reasons why some regulatory differentiation between transgenic and gene-edited organisms is warranted. The argument of this article is not that transgenesis and gene editing are identical. It is that the current binary architecture—full GMO regulation or no regulation, determined by process rather than product—fails to track the actual differences in a proportionate way.

Start with foreign DNA and ecological novelty. When transgenesis introduces a gene from a phylogenetically distant organism—a bacterial cry gene into maize, an antifreeze protein gene from Arctic flounder into tomato—the resulting organism expresses a protein with no evolutionary precedent in that species' lineage. The ecological interactions of that novel protein (its degradation kinetics in soil, its effects on non-target organisms, its behavior under selection pressure) are unknowns that warrant empirical evaluation. An SDN-1 edit that knocks out an endogenous gene, by contrast, produces a loss-of-function allele within the species' existing phenotypic range. The uncertainty profiles are not equivalent, and a regulatory system that recognizes this difference is responding to real biology, not to political anxiety.

Detectability and enforceability present a separate issue. As argued above, SDN-1 edits are analytically indistinguishable from spontaneous mutations. Transgenic insertions, however, carry molecular signatures—junction sequences, selectable markers, vector backbone fragments—that enable reliable detection by PCR-based methods. This is not a trivial point. A regulatory framework that cannot verify compliance through any available analytical method is structurally deficient. The detectability of transgenic events provides a practical basis for traceability that SDN-1 edits cannot offer, and regulators are not irrational to treat enforceable and unenforceable categories differently.

Then there is the question of initial uncertainty profiles. Random transgene insertion into the genome can disrupt endogenous gene function, create read-through transcripts, or produce position effects that alter expression patterns in unpredictable ways. Modern molecular characterization can identify and screen out such events, but the initial uncertainty associated with random genomic integration remains higher than that of a sequence-defined SDN-1 edit at a known locus. This was, historically, a reasonable basis for requiring more extensive characterization of transgenic events.

None of these distinctions, however, justifies the regulatory architecture that currently prevails. The ecological novelty argument supports scrutiny of novel traits, not novel techniques. An SDN-3 edit inserting a gene from a distant taxon presents the same ecological novelty concerns as classical transgenesis and should receive equivalent oversight. The detectability argument supports different compliance and traceability mechanisms, not different safety standards. The initial uncertainty argument has been substantially eroded by four decades of transgenic crop data showing that molecular characterization effectively identifies problematic insertion events. What these distinctions collectively support is a tiered, product-based system that calibrates oversight to the biological properties of each specific modification—precisely what the current blanket frameworks fail to deliver.

The Precautionary Principle Does Not Rescue the Distinction

The strongest defense invokes the precautionary principle: novel technologies warrant heightened scrutiny until safety is established. This principle has legitimate force. It does not, however, support the regulatory architecture under examination. Three reasons explain why.

First, the precautionary principle, as codified in EU law, requires proportionality. Precaution is not a license for indefinite regulatory conservatism. It demands restrictions be calibrated to the magnitude of potential harm and revised as evidence accrues. The European Food Safety Authority has now conducted a systematic literature scan covering January 2022 through May 2025 and concluded no newly published study identified hazards or risks from gene-edited plants not already considered in its existing scientific opinions. Continued application of maximal regulatory scrutiny to SDN-1 edits has passed the point of being precautionary. It is now obstructive.

Second, the precautionary principle addresses uncertainty about outcomes, not discomfort with processes. If two plants are molecularly identical—one produced by CRISPR, one by chemical mutagenesis—they present identical ecological and food-safety profiles. Directing precaution at the process rather than the product does not manage risk. It manages political discomfort with a technology whose name carries cultural baggage "mutation breeding" does not carry.

Third, invoking precaution selectively distorts the risk calculus. Conventional mutagenesis, explicitly exempted from GMO regulations worldwide, introduces thousands of random, uncharacterized mutations per treated genome. The off-target mutation burden of EMS-treated barley or gamma-irradiated rice dwarfs that of a CRISPR-edited line by orders of magnitude. If precaution justifies strict regulation of a technique introducing one or two off-target mutations, the same logic should demand far stricter regulation of techniques introducing thousands. That it does not reveals the asymmetry for what it is: a political accommodation dressed in the language of scientific caution.

The Opportunity Cost Is Measurable and Growing

Regulatory incoherence is not costless. The delay between scientific capability and regulatory approval represents foregone agricultural productivity, foregone nutritional improvement, and foregone climate adaptation. These costs fall disproportionately on the countries least equipped to absorb them.

Consider three concrete examples. CRISPR-edited wheat varieties with reduced asparagine content, and therefore reduced acrylamide formation during baking (a known dietary carcinogen), have been developed and field-tested. Under Japan's or Argentina's frameworks, these could reach farmers within two to three years. Under the EU's pre-2028 framework, they face a timeline of eight to twelve years, assuming authorization is granted. CRISPR-edited rice with enhanced photosynthetic efficiency under high-temperature stress has been demonstrated in controlled environments. Drought-tolerant gene-edited maize lines have been developed by public-sector breeding programs in sub-Saharan Africa. In each case, the bottleneck is not scientific validation. It is regulatory architecture.

The distributional consequences are stark. Public-sector breeders in low-income countries cannot absorb compliance costs of a full GMO regulatory process. A 2023 survey in New Phytologist documented that 114 of 196 United Nations member states have no legislation governing genome editing in crops. Many are in sub-Saharan Africa and South Asia, where the need for climate-adapted crop varieties is most acute. The regulatory models adopted by the EU and US function as de facto templates. When those templates impose process-based restrictions that lack scientific justification, they propagate regulatory barriers into the agricultural systems where gene editing could deliver the greatest benefit.

The economic asymmetry compounds the problem. Multinational seed companies navigate the GMO regulatory apparatus. They have regulatory affairs divisions, legal teams, and capital to sustain a decade-long approval pipeline. Small and medium-sized breeding enterprises and public research institutions do not. Treating gene-edited crops as GMOs concentrates innovation within multinational corporations capable of absorbing compliance costs. This is the precise opposite of the democratization that gene editing's low cost and technical accessibility should enable.

What a Scientifically Coherent Framework Would Look Like

The path forward is not deregulation. It is regulation organized around the right variable. A scientifically defensible framework would assess the product—the organism, its traits, its ecological interactions—rather than the process by which it was produced. This is not radical. Canada has operated under this framework for decades, classifying organisms as "plants with novel traits" irrespective of whether those traits were introduced by transgenesis, mutagenesis, or conventional crossing.

A product-based framework would impose proportional oversight. An SDN-1 edit producing a loss-of-function mutation in an endogenous gene—the type of modification most commonly produced by CRISPR in crop plants—would receive the same regulatory treatment as the same mutation arising from EMS mutagenesis: a notification, characterization of the intended trait, and standard variety registration. A transgenic insertion of a gene from a distant taxon, conferring a trait with no precedent in the recipient species' gene pool, would warrant environmental risk assessment, compositional analysis, and post-market monitoring. Not because transgenesis is inherently dangerous, but because the novelty of the expressed trait creates genuine uncertainty demanding evaluation.

The EU's NGT proposal, with its Category 1/Category 2 distinction, moves in this direction. So does Argentina's case-by-case determination system, which evaluates whether a gene-edited organism contains novel genetic combinations before deciding whether GMO regulations apply. These frameworks are imperfect. The Category 1 criteria, which exclude herbicide-tolerance traits regardless of molecular mechanism, introduce their own scientifically questionable carve-outs driven by political rather than risk-based considerations. But they represent structural improvement over blanket process-based triggers because they attempt to calibrate regulatory scrutiny to the biological properties of the organism rather than to the laboratory technique recorded in the developer's notebook.

Conclusion: The Case for Risk-Proportionate Governance

The blanket regulatory asymmetry between transgenic and gene-edited crops is a historical artifact that has outlived whatever scientific justification it once possessed. It was defensible in 1990, when recombinant DNA was the only technique capable of introducing heritable genetic changes unachievable by conventional breeding, and when the uncertainty surrounding random genomic insertion warranted a distinct regulatory tier. It is not defensible in 2026. SDN-1 modifications produce outcomes molecularly indistinguishable from spontaneous mutations. Whole-genome sequencing demonstrates they carry fewer off-target effects than the conventional mutagenesis techniques explicitly exempted from regulation. The European Food Safety Authority's own systematic literature reviews have identified no novel hazards attributable to the gene-editing process itself.

This does not mean all regulatory differentiation should be abandoned. Foreign DNA, ecological novelty, and the expression of proteins with no evolutionary precedent in a recipient species' lineage are legitimate triggers for empirical safety evaluation. An SDN-3 insertion of a synthetic gene cassette from a distant taxon warrants environmental risk assessment and compositional analysis—not because the insertion technique is dangerous, but because the trait it introduces is genuinely novel. Detectability differences between transgenic events and SDN-1 edits justify different traceability and compliance mechanisms. These are real biological and practical distinctions, and a credible regulatory framework should reflect them.

What cannot be justified is the binary architecture that most jurisdictions still maintain: full GMO regulation triggered by process, or no regulation at all. The evidence reviewed here supports a tiered, product-based system in which regulatory scrutiny is proportional to the biological novelty and uncertainty associated with each specific modification. SDN-1 edits producing loss-of-function mutations within a species' existing allelic range should receive notification-only treatment, equivalent to conventional mutagenesis. SDN-2 edits introducing alleles from the species' gene pool warrant light-touch characterization. SDN-3 insertions and transgenic events introducing cross-species genetic material should face proportional environmental and food-safety assessment calibrated to the novelty of the expressed trait.

The costs of continued incoherence are not abstract. They are measured in delayed deployment of climate-adapted crop varieties, in the concentration of innovation within multinational corporations capable of absorbing decade-long compliance pipelines, and in the propagation of scientifically unjustified regulatory templates into the developing countries where gene editing could deliver the greatest benefit. The precautionary principle does not require treating a single-nucleotide knockout the same as a transgenic insertion of a bacterial toxin gene. It requires calibrating scrutiny to actual risk. By that standard, the current blanket asymmetry fails—not because differentiation is wrong, but because the differentiation we have is aimed at the wrong variable.

The question is no longer whether regulatory reform is needed. The EU's own NGT proposal, Argentina's case-by-case framework, and Health Canada's product-based system have each conceded as much. The question is how quickly the remaining jurisdictions will replace process-based triggers with risk-proportionate governance—and how much agricultural innovation will be foregone in the interim.